Zenas BioPharma, Inc. (ZBIO) SEC Filings & Earnings Calls

Clinical-stage company with no approved products; obexelimab still investigational; Phase 2 SunStone SLE topline results pending.

“Phase 2 SunStone trial in SLE topline results expected in 4Q 2026.”

activist exit / reduced ownership

“The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on August 19, 2026.” · word for word

Pre-commercial stage with no product revenue; net loss of $24.1M; reliance on BLA approval and future commercialization.

“Net loss was $24.1 million for the quarter ended June 30, 2026”

Regulatory risk: obexelimab BLA under FDA review with PDUFA May 2027; potential for delay or non-approval.

“BLA has a Prescription Drug User Fee Act (PDUFA) target action date of May 27, 2027” · word for word

Clinical and Regulatory Risk

“We have no product candidates approved for commercial sale in any country, and we have not generated any revenues from the sale of products.” · word for word

Significant Operating Losses

“We have incurred significant operating losses and negative cash flows since inception. Our net losses for the three and six months ended June 30, 2026 were $111.5 million and $192.4 million, respectively.” · word for word

Dependence on Future Financing

“We will need to continue to raise substantial additional capital to support our continuing operations and pursue our growth strategy as a public company.” · word for word

Tariff Impact on Costs

“We import drug products and other components from and into China for use in the manufacturing process and in our clinical studies, and such components and products are subject to tariffs, which we anticipate will result in increased costs.” · word for word

Tariff-induced cost increases

“we import drug products and other components from and into China for use in the manufacturing process and in our clinical studies, and such components and products are subject to tariffs, which we anticipate will result in increased costs.” · word for word

Clinical trial failure risk

“We may never obtain regulatory approval for any product candidates that we develop.” · word for word

Need for additional capital

“We will need to continue to raise substantial additional capital to support our continuing operations and pursue our growth strategy as a public company.” · word for word

No product revenue until at least 2027

“we do not expect to generate revenue from sales of any product candidates or from other sources until 2027 at the earliest, if at all.” · word for word

Insider ownership concentration

“Insider (Chairman/CEO) holds 4.794% of shares, with additional control via Tellus and trust.”

Increased leverage and potential dilution from convertible notes and equity offering.

“Convertible notes and equity offering increase financial obligations and share count.”

Significant future milestone and royalty obligations

“We are further obligated to pay future regulatory and commercial milestones of up to $723.0 million related to orelabrutinib, and future development, regulatory, and commercial milestones of up to $656.0 million... for each preclinical compound if certain milestones are successfully achieved. In addition, we are obligated to pay royalties on net sales at rat” · word for word

Potential dilution from InnoCare milestone shares

“We are also required to make an additional one-time non-refundable cash payment of $25.0 million and issue an additional 2,000,000 shares of common stock to InnoCare upon the occurrence of Zenas’ Phase 3 clinical trial for orelabrutinib in any indication other than primary progressive MS, or by March 31, 2026” · word for word

Going concern uncertainty

“management has concluded that these resources are not sufficient to alleviate substantial doubt with respect to our ability to continue as a going concern.” · word for word

Tariff cost increase on China imports

“We import drug products and other components from and into China for use in the manufacturing process and in our clinical studies, and such components and products are subject to tariffs, which we anticipate will result in increased costs.” · word for word

Drug pricing reform (IRA) impact

“The Inflation Reduction Act ('IRA'), includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D... a drug price negotiation program for certain high spend Medicare Part B and D drugs (with negotiated prices for the first set of drugs taking effect in 2026).” · word for word

Clinical-stage company with no approved products; regulatory and commercial execution risks.

“clinical-stage global biopharmaceutical company” · word for word

Debt facility carries interest and conditions; potential dilution if milestones not met.

“mid-single digit interest payments over SOFR; additional $175 million subject to regulatory and commercial conditions”

No material risk signals; plan is discretionary and subject to clawback policy.

Clinical trial success reduces pipeline risk but regulatory and commercial risks remain

“BLA submission planned Q2 2026; regulatory approval and market adoption still uncertain”

Potential dilution from future equity grants under inducement plan.

“Plan authorizes up to 1,000,000 shares for inducement grants.”

Clinical trial failure risk for obexelimab in IgG4-RD and SLE; pipeline dependency on single lead asset.

“Phase 3 INDIGO trial topline results expected around year-end 2025; Phase 2 SunStone trial enrollment ongoing.”

No approved products or revenue; reliance on financing and partnerships.

“Clinical-stage company with no commercial revenue; funding agreements subject to milestones.”

Going concern risk

“The Company has concluded that substantial doubt exists with respect to its ability to continue as a going concern.” · word for word

Cash burn risk

“Net cash used in operating activities $119.9M for nine months ended September 30, 2025.”

Dependence on future financing

“The Company will need to raise additional capital to finance its operations.” · word for word

Clinical trial risk: positive Phase 2 results may not translate to Phase 3 success or regulatory approval.

“Obexelimab met the primary endpoint... Zenas also expects to report topline results from the obexelimab Phase 3 INDIGO trial in IgG4-RD around year-end 2025”

Competitive risk: multiple approved therapies exist for RMS, and obexelimab must demonstrate differentiation.

“RMS is characterized by distinct episodes of new or worsening neurological symptoms... Approximately 85% of patients are initially diagnosed with RMS.” · word for word